CRISPR/Cas9 screening and pharmacologic inhibition studies confirmed that ABCC1 loss sensitizes AML cells to BCL2 inhibition, including in venetoclax-resistant models. This evidence concerns the gene BCL2 and acute myeloid leukemia.